ChromoCure retains Patent & Intellectual Property Attorneys to assess its Intellectual Property portfolio

ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections. A complex and innovative series of systems, processes, cell preparation techniques and diagnostic algorithms are currently integrated in ChromoCure's landmark Chromosomal Scanning Technology.

The Company recently announced it will accelerate the implementation of its Cancer Therapy and Cure initiatives. The Intellectual Property audit and subsequent Patent Applications and protections will provide the required foundation for various research programs and collaborations.

ChromoCure's chromosomal approach to cancer detection, therapy and cure has been validated by recent publications, including the Mayo Clinic findings. Per the publication of the company's clinical collaboration and testing, its proprietary Chromosomal Scanner technology was demonstrated a reliable and effective automated technological system to detect aneuploid cells in real-world specimens, that detection of aneuploid cells is diagnostic of cervical lesions and that the Chromosomal Scanner possesses superb performance at not only detecting cancer but achieving the near theoretical maximum agreement with the collaborating clinic's error containing data.

The Company's pioneering knowledge of cancer's chromosomal properties invites very effective, non-toxic therapeutic strategies. ChromoCure's understanding of cancer's chromosomal peculiarities provides the most promising avenue for treatment and cure and reinforces its pioneering status.